F106 and L108 of P22 were predicted to be the key residues to maintain P22’s binding to FOXM1 C-terminus (Fig. 2D) and the synthesized M1-21 mutant (M1-21mut, F106A, and L108A) (Fig. S9) lost the ability to bind to FOXM1 C-terminus or to inhibit cancer cells (Fig. S10). This evidence concerns the gene FOXM1 and cancer.